FDA Fast Tracks Two New Lung Cancer Drugs

The FDA has fast-tracked two personalized non-small cell lung cancer drugs from Boehringer Ingelheim and Roche/Astellas, putting the products on track for approval in the third quarter of this year.
PM Live